Effects of Food and Drug Administration‐approved medications for Alzheimer's disease on clinical progression
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Observational studies suggest that cholinesterase inhibitors and/or memantine may delay clinical progression of Alzheimer's disease (AD) in 40% of individuals taking the medications. Given this response and existence of side effects, we sought to quantify medication use and benefits in a population‐based study of incident AD cases. Methods: The Cache County Dementia Progression Study enrolled and followed a cohort of 327 incident AD cases for a maximum of 9 years. Drug exposure was expressed using a persistency index (PI), calculated as total years of drug use divided by total years of observation. Linear mixed‐effects models examined PI, and interactions with sex and apolipoprotein E (APOE) as predictors of clinical progression on the Mini‐Mental State Examination and Clinical Dementia Rating‐Sum of Boxes. Results: A total of 69 participants (21.1%) reported having ever used cholinesterase inhibitors or memantine. There was a strong three‐way interaction between PI, sex, and time. Among women, a higher PI (i.e., greater duration of use) of cholinesterase inhibitors was associated with slower progression on the Mini‐Mental State Examination and Clinical Dementia Rating‐Sum of Boxes, particularly among those with an APOE ε4 allele. In contrast, higher PI was associated with faster progression in males. Conclusion: A low percentage of individuals with AD in the community are taking cholinesterase inhibitors or memantine. This study suggests that women, particularly those with an APOE ε4 allele, may benefit the most from these medications. With the newly approved increased dose of donepezil, it will be imperative to determine whether a higher dose is needed in men or whether other factors warrant consideration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
APOE -ε4 count predicts age when prevalence of AD increases, then declines: The Cache County Study
Breitner, J. C. S., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C., Norton, M. C., Tschanz, J. T., Plassman, B. L., Meyer, M. R., Skoog, I., et al. (1999) · Neurology · doi:10.1212/wnl.53.2.321 · Cited by 397
Self-citationTschanz, J. T., Corcoran, C. D., Schwartz, S., Treiber, K., Green, R. C., Norton, M. C., Mielke, M. M., Piercy, K., Steinberg, M., Rabins, P. V., et al. (2011) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181faec23 · Cited by 244
Self-citationRountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181 · cited 3×
“Rountree et al [23] previously reported that higher PIs were associated with better performance on cognitive and functional outcomes.”
BackgroundMethodInfluentialAgüero‐Torres, H., Fratiglioni, L., Guo, Z., Viitanen, M., & Winblad, B. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb02464.x · Cited by 147 · cited 1×
“This is interesting in light of the fact that women with AD have been found to have a faster decline than men when cholinesterase use is not considered [12,25].”
BackgroundRacial and Ethnic Disparities in the Treatment of Dementia Among Medicare Beneficiaries
Zuckerman, I. H., Ryder, P. T., Simoni-Wastila, L., Shaffer, T., Sato, M., Zhao, L., & Stuart, B. (2008) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/63.5.s328 · Cited by 102
Cited by
Uddin, M. S., Rahman, M. M., Jakaria, M., Rahman, M. S., Hossain, M. S., Islam, A., Ahmed, M., Mathew, B., Omar, U. M., Barreto, G. E., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01911-8 · Cited by 156
Rattinger, G. B., Fauth, E. B., Behrens, S., Sanders, C., Schwartz, S., Norton, M. C., Corcoran, C., Mullins, C. D., Lyketsos, C. G., & Tschanz, J. T. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.008 · Cited by 39
“For example, earlier DPS findings suggested that the use of cognitively stimulating activities is associated with slower decline in dementia [35], as are vascular treatments [36,37], and the use of cognitive enhancing medications [38].”
BackgroundSelf-citationGuo, H., Wang, G., Zhai, Z., Huang, J., Huang, Z., Zhou, Y., Xia, X., Yao, Z., Huang, Y., Zhao, Z., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123809 · Cited by 31
Pirker-Kees, A., Dal-Bianco, P., & Schmidt, R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181102 · Cited by 17
Metadata
- Authors
- Mielke, M. M., Leoutsakos, J., Corcoran, C. D., Green, R. C., Norton, M. C., Welsh‐Bohmer, K. A., Tschanz, J. T., & Lyketsos, C. G.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2012-02-03
- Volume
- 8
- Issue
- 3
- Pages
- 180-187
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2766184965
- Cited by
- 52
- References
- 6
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Food and Drug Administration‐approved medications for Alzheimer's disease on clinical progression. https://app.cochat.ai/papers/10.1016/j.jalz.2011.02.011
- The paper
- Mielke, M. M., Leoutsakos, J., Corcoran, C. D., Green, R. C., Norton, M. C., Welsh‐Bohmer, K. A., Tschanz, J. T., & Lyketsos, C. G. (2012). Effects of Food and Drug Administration‐approved medications for Alzheimer's disease on clinical progression. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2011.02.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.